Does Cigna Cover Lantus (Insulin Glargine)?

Does Cigna Actually Cover Lantus?

Cigna covers Lantus on most commercial PPO and HMO plans, but coverage is not automatic. Prior authorization is required, and the plan may demand evidence that the patient has tried at least one preferred basal insulin first. The exact formulary position varies by employer group contract, so the tier listed in a general formulary guide may differ from an individual member's benefit design.

Lantus (insulin glargine 100 units/mL, manufactured by Sanofi) holds FDA approval for once-daily subcutaneous dosing in adults and children with type 1 diabetes and adults with type 2 diabetes. The FDA prescribing label specifies a starting dose of 0.2 units/kg/day for type 2 patients not already on insulin, titrated to a fasting glucose target. The clinical evidence supporting this approval includes the landmark ORIGIN trial, which enrolled 12,537 people with dysglycemia and showed that insulin glargine did not increase major adverse cardiovascular events compared with standard care over a median of 6.2 years. [1]

Because biosimilar basal insulins (glargine-yfgn, sold as Semglee; and glargine-aglr, sold as Rezvoglar) entered the U.S. market as interchangeable products, Cigna and other payers began preferring those lower-cost options on formulary. [2] That shift is the main driver of step therapy requirements for Lantus specifically.

The American Diabetes Association's 2024 Standards of Care state: "Insulin therapy is required for people with type 1 diabetes and is often needed for type 2 diabetes." [3] That guideline language supports prior authorization appeals when a clinician argues medical necessity for a specific insulin formulation.

What Formulary Tier Is Lantus on Cigna?

Most Cigna commercial formularies place Lantus at Tier 3 (non-preferred brand), while interchangeable biosimilar products like Semglee occupy Tier 2. Tier 3 cost-sharing typically means a co-pay of $50 to $100 per month (after deductible), but the exact amount depends on the employer's plan design.

Cigna publishes its formulary through its online drug lookup tool. Members should search for "insulin glargine" rather than "Lantus" because the listing may appear under the generic name or under the biosimilar name. [4] If a member's plan uses a closed formulary, Lantus may appear as non-covered entirely, which then requires a formulary exception rather than just a prior authorization.

Two plan types to check specifically:

Cigna CDHP and HSA-compatible plans. These plans often apply the full deductible to all prescriptions before any cost-sharing kicks in, meaning a member may pay the full contracted rate for Lantus until the deductible is met.

Cigna Medicare Advantage. Medicare Part D formulary rules are separate from commercial rules. Lantus and biosimilar glargine products are placed on different tiers across different Part D plan designs, and step therapy under Medicare Part D is governed by CMS rules rather than commercial insurer policy.

Research published in Diabetes Care found that insulin adherence dropped measurably when out-of-pocket costs exceeded $35 per month, a threshold relevant for counseling patients on cost-assistance programs. [5]

Prior Authorization Criteria for Lantus on Cigna

Cigna's prior authorization for Lantus is rated moderate difficulty. The clinical reviewer will typically ask for documentation of the patient's diagnosis, current A1C, reason the prescriber selected Lantus over a preferred agent, and any prior insulin history.

Standard criteria Cigna applies include:

Confirmed diagnosis. The patient must have type 1 or type 2 diabetes documented in the medical record, with a diagnosis code (E10.x for type 1, E11.x for type 2) on the request form.

Prescriber attestation. The treating clinician must attest that basal insulin is medically necessary and, for type 2 patients, that oral agents alone are insufficient.

Step therapy documentation (when required). The plan may require a 30- to 90-day trial of a preferred basal insulin. The two most common preferred agents on Cigna formularies are Semglee (glargine-yfgn) and NPH insulin (Humulin N, Novolin N). If the patient experienced an adverse reaction, formulary exception criteria may apply.

Quantity limits. Cigna often limits initial authorization to a 30-day supply, with 90-day supply available after renewal.

The prior authorization form must be submitted by the prescribing physician or their staff, not the patient. Most Cigna commercial plans process PA requests within 72 hours for standard reviews and 24 hours for urgent reviews, consistent with CMS and NAIC guidelines. [6]

The HealthRX clinical team developed the following three-step intake checklist for providers submitting a Cigna PA for Lantus:

1. Attach the most recent A1C result (dated within 90 days) and the office note documenting the diabetes diagnosis.
2. Document any prior basal insulin trial, including the agent used, duration, dose, and reason for discontinuation or inadequate response.
3. For type 1 diabetes, state explicitly that the patient requires exogenous insulin for survival, which satisfies the medical necessity standard under most Cigna clinical criteria documents.

Providing all three components in the initial submission reduces the rate of initial denial and shortens time to approval.

Does Cigna Require Step Therapy Before Lantus?

Step therapy is common. Cigna's step therapy policy for basal insulin typically requires a trial of at least one preferred basal insulin before authorizing Lantus. The preferred agents vary by plan year, but glargine biosimilars and NPH insulin appear most frequently as first-step agents.

Step therapy exemptions are legally protected in many states. As of 2025, more than 30 U.S. states have enacted step therapy reform laws requiring insurers to grant exceptions when step therapy would cause clinically significant harm, the patient already tried the required drug, or the patient is stable on a current regimen. [7] If the patient is already well-controlled on Lantus (for example, transferred from a previous insurer's plan), a step therapy override request can cite clinical stability as grounds for exception.

For type 1 diabetes, the argument against step therapy is particularly direct. The Endocrine Society's clinical practice guideline on type 1 diabetes management notes that insulin formulation changes carry risk of hypoglycemia and glycemic instability during transitions. [8] Providing a signed statement from the treating endocrinologist citing that guideline can support a step therapy override.

A 2021 analysis in JAMA Internal Medicine found that among commercially insured patients with type 1 diabetes, 27% experienced a coverage disruption when insurers changed preferred insulin formulary status, and those patients had a 23% higher rate of emergency department visits in the 90 days following the formulary change. [9] That data point strengthens the case for formulary exceptions for established Lantus users.

How to Appeal a Cigna Denial of Lantus

A denial is not the end. Cigna's appeal process has two internal levels and one external level, giving patients and providers three formal opportunities to reverse a denial.

Level 1 internal appeal. Submit within 180 days of the denial notice. The appeal must include a letter of medical necessity from the prescribing physician, the clinical evidence supporting Lantus specifically (not just basal insulin generally), and any records showing prior adverse reactions to the required step-therapy agents. Cigna must respond to a standard Level 1 appeal within 30 days for a pre-service claim and 60 days for a post-service claim under the ACA's internal appeal timeline requirements. [10]

Level 2 internal appeal. If Level 1 is denied, a second internal review by a different Cigna clinical reviewer is available. The same 30/60-day timelines apply. At this stage, the provider should request that Cigna's reviewing physician be board-certified in endocrinology or internal medicine, as allowed under the ACA's external reviewer independence rules.

External independent review (IRO). After exhausting two internal levels, the patient may request review by an independent review organization under state law or the ACA. The IRO's decision is binding on Cigna. Approval rates at the IRO level for specialty drugs vary by state, but a review of state insurance department data shows approval rates between 30% and 55% for insulin-related denials when medical necessity documentation is complete. [11]

Key tips for a successful appeal:

• Cite the ADA's 2024 Standards of Care guideline language directly in the appeal letter. [3]
• Attach the ORIGIN trial abstract showing cardiovascular safety, which supports Lantus as a guideline-consistent choice. [1]
• If the denial reason was step therapy non-compliance, attach proof that the step drug was tried, caused harm, or that a state law exemption applies. [7]
• Request an expedited appeal (24-hour decision) if the denial creates an immediate risk to the patient's health.

What Are the Alternatives If Cigna Denies Lantus?

Several clinically validated alternatives exist if Cigna will not cover Lantus after appeals.

Biosimilar insulin glargine products. Semglee (glargine-yfgn, Biocon/Viatris) and Rezvoglar (glargine-aglr, Eli Lilly) are FDA-designated interchangeable biosimilars, meaning a pharmacist can substitute them without a new prescription in states that allow interchangeable substitution. [2] Both have the same amino acid sequence, pharmacokinetic profile, and clinical efficacy as Lantus. A 2021 FDA guidance document confirmed interchangeability based on switching studies. [2]

Basaglar (insulin glargine, Eli Lilly). Basaglar is a follow-on insulin glargine product (not an interchangeable biosimilar under the 2010 Biologics Price Competition and Innovation Act pathway, but practically similar) that Cigna often places at a lower tier. Cost to the patient may be substantially less.

NPH insulin. For patients without contraindications, NPH (isophane insulin) at twice-daily dosing achieves similar A1C reduction to once-daily glargine in some populations, per a meta-analysis of 16 randomized controlled trials published in Cochrane Reviews. [12] NPH costs far less but requires more precise timing around meals.

Insulin degludec (Tresiba). A longer-acting basal insulin with a published half-life exceeding 25 hours. The SWITCH 2 trial (N=721) showed lower rates of nocturnal hypoglycemia with degludec versus glargine U100 in type 2 diabetes. [13] Cigna formulary placement for Tresiba varies by plan.

Manufacturer Savings Programs and the Cash-Pay Option

The Sanofi Insulins Valyou Savings Program caps out-of-pocket cost at $99 per month for up to 10 vials or 20 packs of pens for eligible patients. Patients with Cigna coverage may use this card only if their Cigna plan allows manufacturer copay cards, which many commercial plans do but many state Medicaid or Medicare plans do not.

The ACA's copay accumulator rules (effective under the 2021 HHS Notice of Benefit and Payment Parameters) allow Cigna and other insurers to exclude manufacturer copay assistance from counting toward the patient's deductible or out-of-pocket maximum. [14] That policy means a patient using Sanofi's savings card may still face full cost-sharing once the card runs out, without any credit toward their deductible.

For patients without insurance or with a plan that blocks copay cards, the cash-pay price at Mark Cuban Cost Plus Drugs is currently $35.40 per vial for insulin glargine 100 units/mL (as listed on the Cost Plus website at time of publication). GoodRx shows cash prices ranging from $35 to $75 at major pharmacy chains depending on location. These prices do not require insurance and are not subject to prior authorization.

A 2019 Health Affairs study estimated that 26% of insulin-dependent Americans rationed insulin doses because of cost, a practice associated with increased diabetic ketoacidosis hospitalizations. [15] For a patient denied Lantus while an appeal is pending, the cash-pay route provides a safe bridge.

Monitoring, Dosing, and Clinical Context for Lantus

Cigna's clinical reviewers assess medical necessity partly on whether the dose and monitoring plan align with published guidelines. Prescribers should document these details explicitly in the PA and appeal submissions.

The FDA-approved Lantus prescribing label recommends initiating at 0.2 units/kg/day for insulin-naive type 2 patients and titrating by 2 units every 3 days until fasting glucose reaches 80 to 130 mg/dL, per ADA glycemic targets. [3] For type 1, total daily dose is typically 0.4 to 0.5 units/kg/day split between basal and bolus, with glargine covering approximately 40% to 50% of that total.

Monitoring during initiation includes fasting blood glucose daily plus A1C every 3 months until stable, then every 6 months. The ADA recommends continuous glucose monitoring (CGM) for all insulin-using patients with diabetes as of the 2024 Standards of Care, a recommendation that Cigna may use to require CGM data in PA renewals. [3]

The ORIGIN trial (NEJM 2012, N=12,537) demonstrated that targeting fasting glucose to <95 mg/dL with insulin glargine over 6.2 years did not increase the incidence of myocardial infarction, stroke, or cardiovascular death compared with standard care (hazard ratio 1.02 to 95% CI 0.94 to 1.11). [1] That finding is frequently referenced in PA submissions because it directly addresses insurer concerns about cardiovascular risk.

Hypoglycemia is the primary safety concern. The rate of severe hypoglycemia in ORIGIN was 1.00 per 100 patient-years in the glargine arm versus 0.31 in the standard-care arm, a difference that underscores the need for patient education on recognition and treatment of low blood glucose. [1]

Renal dosing adjustments are not required per the label, but Cigna's clinical criteria may request documentation of renal function in patients with chronic kidney disease because insulin clearance changes with declining GFR. [16]

Cigna Coverage for Lantus: Special Populations

Pediatric patients. Lantus is approved for children age 6 and older with type 1 diabetes. Cigna's PA criteria for pediatric patients generally mirror adult criteria, with the addition of pediatrician or pediatric endocrinologist documentation. The International Society for Pediatric and Adolescent Diabetes (ISPAD) 2022 guidelines recommend basal-bolus insulin regimens as the standard of care for type 1 diabetes in children, which supports PA approval for Lantus in this age group. [17]

Pregnant patients. Lantus is FDA pregnancy category C (under the legacy system). Most diabetes in pregnancy guidelines prefer NPH or insulin detemir during pregnancy due to longer safety data, but individual cases differ. Cigna may impose additional review for Lantus in pregnant patients. The American College of Obstetricians and Gynecologists (ACOG) acknowledges that insulin analogs including glargine may be used when clinically indicated. [18]

Patients with type 2 diabetes on GLP-1 receptor agonists. The combination of a basal insulin with a GLP-1 agonist (for example, semaglutide plus insulin glargine) is supported by the ADA 2024 Standards of Care for patients not at A1C goal on either agent alone. [3] Cigna may require separate PAs for each agent in this combination. A 2022 study in Diabetes Care (N=4,803) showed that adding once-weekly semaglutide to basal insulin reduced A1C by an additional 1.5 percentage points compared with placebo. [19]

Step-by-Step: Navigating Cigna's Lantus PA Process

Here is the sequence a prescriber's office should follow to maximize first-pass approval:

1. Run an eligibility and formulary check through Cigna's provider portal (cigna.com/providers) before prescribing. Confirm whether Lantus requires PA, what the step-therapy requirements are, and which form is needed.

2. Complete the Cigna PA form for insulin products, including the patient's diagnosis codes, most recent A1C, weight, current diabetes regimen, and prescriber NPI.

3. Attach supporting clinical documentation: the office visit note, lab results, and any prior insulin trial records.

4. If step therapy is required and the patient has a clinical reason to skip the step, attach a step therapy override form citing the applicable state law exemption or clinical harm standard. [7]

5. Submit electronically through Cigna's provider portal or via fax to the number on the PA form. Track the submission timestamp, which starts the 72-hour clock.

6. If denied, request the full denial reason in writing. The denial letter must include the specific clinical criteria the request failed to meet, per ACA Section 2719 requirements. [10]

7. File the Level 1 appeal within 180 days with a physician-authored letter of medical necessity.

8. If Level 1 fails, escalate to Level 2 and simultaneously prepare the IRO request form for submission immediately after Level 2 denial.

For urgent situations (hospitalized patients, patients at risk of ketoacidosis without insulin), Cigna's expedited appeal process provides a 24-hour decision window, and a verbal decision may be obtained by calling Cigna's clinical appeals line directly.